Allosteric Modulators Global Market Report 2026

Allosteric modulators are substances that interact with receptors or proteins at binding sites distinct from the primary active, or orthosteric, site and modify receptor function by increasing or decreasing the response to naturally occurring ligands. By altering receptor structure and downstream signaling processes without directly engaging the main binding site, these modulators can provide enhanced selectivity and may reduce the likelihood of adverse effects compared with traditional therapeutic agents.

The primary types of allosteric modulators include positive allosteric modulators, negative allosteric modulators, and silent allosteric modulators. Positive allosteric modulators are compounds that attach to a binding site separate from the active site of a target protein and increase its biological response or activity. These modulators are applied in areas such as neurological disorders, oncology, cardiovascular diseases, metabolic disorders, and other therapeutic fields, and they are used by end users including pharmaceutical companies, biotechnology companies, academic institutions, research organizations, and others.

Tariffs are influencing the allosteric modulators market by increasing the cost of importing key research inputs such as advanced chemical reagents, laboratory instruments, and specialized pharmaceutical synthesis equipment required for drug discovery and development. This is slowing research timelines and raising R&D expenses, particularly in regions dependent on imported high-precision laboratory infrastructure such as Asia-Pacific and Latin America. Pharmaceutical companies, biotechnology firms, and academic research institutes are most affected due to reliance on global supply chains for drug screening and molecular modeling tools. However, tariffs are also encouraging local production of research chemicals, expansion of domestic biotech manufacturing capabilities, and increased investment in regional drug discovery ecosystems, supporting long-term innovation resilience.

The allosteric modulators market size has grown rapidly in recent years. It will grow from $1.82 billion in 2025 to $2.05 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to growing demand for safer alternative mechanisms in drug development, early-stage research in receptor binding modulation, increasing focus on neurological disorder treatment innovation, advancements in G-protein coupled receptor studies, and expansion of small molecule drug discovery programs.

The allosteric modulators market size is expected to see rapid growth in the next few years. It will grow to $3.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to the expansion of AI-enabled drug discovery platforms, increasing investments in precision medicine and targeted therapeutic development, rising number of clinical trials focused on allosteric modulators, growth in computational biology and structural pharmacology capabilities, and increasing demand for highly selective drugs with reduced side effects. Major trends in the forecast period include wider adoption of structure-based drug design for identifying allosteric modulators, growing utilization of computational chemistry and AI-based molecular screening for receptor targeting, expansion of allosteric modulator research in neurological disorder treatments, rising development of highly selective receptor subtype-specific modulators, and increasing pharmaceutical focus on next-generation safer non-orthosteric drug mechanisms.

The increasing burden of neurological disorders and disability is expected to propel the growth of the allosteric modulators market going forward. Neurological disorders and disability refer to medical conditions affecting the brain, spinal cord, and nervous system that result in cognitive, sensory, or physical impairments. The burden of neurological disorders and disability is increasing due to rising chronic disease prevalence and growing lifestyle related health risks. Allosteric modulators are used in neurological disorders to regulate receptor activity and improve neurotransmission, helping manage conditions such as epilepsy, schizophrenia, Parkinson's disease, and anxiety disorders. For instance, in March 2024, according to the Alzheimer's Association, a US-based nonprofit health organization, an estimated 6.9 million Americans aged 65 years and older were living with Alzheimer's disease in 2024, compared to 6.7 million in 2023, reflecting a notable year-on-year increase in disease prevalence. Therefore, the increasing burden of neurological disorders and disability is driving the growth of the allosteric modulators market.

The increasing healthcare spending is expected to propel the growth of the allosteric modulators market going forward. Healthcare spending refers to the total expenditure on medical services, treatments, healthcare infrastructure, pharmaceuticals, and related activities aimed at maintaining or improving health. Healthcare spending is rising due to the increasing prevalence of chronic diseases, as long-term conditions such as diabetes, cardiovascular disorders, and cancer require continuous medical care, advanced treatments, and prolonged hospitalization. Higher healthcare spending supports allosteric modulators by expanding funding and reimbursement capacity for advanced precision therapies, enabling greater investment in research, clinical trials, and adoption of novel mechanism-based drugs that target diseases with improved specificity and fewer side effects. For instance, in April 2026, according to the Office for National Statistics, a UK-based government agency, healthcare spending accounted for 11.4% of GDP in 2025, up from 11.1% in 2024. Therefore, the increasing healthcare spending is driving the growth of the allosteric modulators market.

Leading companies operating in the allosteric modulators market are focusing on developing innovative solutions, such as selective allosteric modulator therapeutics to meet the rising demand for safer and more targeted neurological disorder treatments. Selective allosteric modulators bind to receptor sites different from traditional active binding sites enabling improved precision enhanced efficacy and reduced side effects compared to conventional drugs. For example, in April 2024, Neurosterix, a US-based biopharmaceutical company, launched an advanced allosteric modulator drug discovery platform supported by 63 million dollars in Series A financing. The platform focuses on developing highly selective brain-penetrant small molecule therapies including M4 positive allosteric modulators for schizophrenia and other neurological disorders. The technology utilizes high-throughput discovery tools to accelerate the development of next-generation neurological therapeutics with improved tolerability and therapeutic precision.

Major companies operating in the allosteric modulators market are Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Neurocrine Biosciences Inc., Intra-Cellular Therapies, Biohaven Ltd., Nxera Pharma, Kainova Therapeutics, Saniona AB, Addex Therapeutics Ltd., Confo Therapeutics NV

Asia-Pacific was the dominant region in the allosteric modulators market in 2025 and is expected to be the rapidly expanding region in the forecast period. The regions covered in allosteric modulators report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allosteric modulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allosteric modulators market consists of sales of G protein-coupled receptor (GPCR) modulators, ion channel modulators, enzyme modulators, receptor-targeted therapeutics, and small molecule allosteric drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The allosteric modulators market research report is one of a series of new reports from The Business Research Company that provides allosteric modulators market statistics, including allosteric modulators industry global market size, regional shares, competitors with a allosteric modulators market share, detailed allosteric modulators market segments, market trends and opportunities, and any further data you may need to thrive in the allosteric modulators industry. This allosteric modulators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allosteric Modulators Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses allosteric modulators market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allosteric modulators ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The allosteric modulators market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Positive Allosteric Modulators; Negative Allosteric Modulators; Silent Allosteric Modulators
• 2) By Application: Neurological Disorders; Oncology; Cardiovascular Diseases; Metabolic Disorders; Other Applications
• 3) By End User: Pharmaceutical Companies; Biotechnology Companies; Academic And Research Institutes; Other End Users
• Subsegments:
• 1) By Positive Allosteric Modulators: Metabotropic Glutamate Receptor Modulators; Gamma Aminobutyric Acid Receptor Modulators; Nicotinic Acetylcholine Receptor Modulators; Calcium Sensing Receptor Modulators
• 2) By Negative Allosteric Modulators: Serotonin Receptor Modulators; Dopamine Receptor Modulators; Histamine Receptor Modulators; Chemokine Receptor Modulators
• 3) By Silent Allosteric Modulators: Metabotropic Glutamate Receptor Modulators; Gamma Aminobutyric Acid Receptor Modulators; Nicotinic Acetylcholine Receptor Modulators
• Companies Mentioned: Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca PLC; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company; Bayer AG; Takeda Pharmaceutical Company Limited; Amgen Inc.; Boehringer Ingelheim International GmbH; Biogen Inc.; Vertex Pharmaceuticals Incorporated; H. Lundbeck A/S; Neurocrine Biosciences Inc.; Intra-Cellular Therapies; Biohaven Ltd.; Nxera Pharma; Kainova Therapeutics; Saniona AB; Addex Therapeutics Ltd.; Confo Therapeutics NV
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.